150-Patient, Triple-Blinded, Sham-Controlled Study Designed to be Executed in Collaboration with Lindus Health to Support Future FDA Submission for Drug-Free Insomnia Treatment Builds on Prior Peer-Reviewed Clinical Data and International Regulatory Approvals HOUSTON, TX, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Nexalin...
Multiple new federal actions highlight deep brain neurostimulation as a high-priority emerging therapy for TBI, PTSD, stroke recovery, and Alzheimer's diseaseHOUSTON, TX, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the "Company" or "Nexalin"), developer of Deep Intracranial Frequency Stimulation...
New digital health platform being launched in partnership with UCSD allows remote physician-monitored neurotherapy subscription models to expand reach, lower cost, and break down treatment stigma for brain-health disordersHOUSTON, TX, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the "Company"...
New digital health platform being launched in partnership with UCSD allows remote physician-monitored neurotherapy subscription models to expand reach, lower cost, and break down treatment stigma for brain-health disordersHOUSTON, TX, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the "Company"...
Peer-Reviewed Imaging Across Multiple Indications Validates Nexalin's Ability to Modulate Deep Brain Networks, Differentiating It from other Superficial Neurostimulation TechniquesHOUSTON, TX, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the "Company" or "Nexalin"), the leader in non-invasive Deep Intracranial Frequency...
HOUSTON, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the "Company" or "Nexalin"), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has received a notification letter (the "Notification Letter") from the...
Four weeks of non-invasive DIFS™ neurostimulation delivers meaningful attention gains alongside objective brain imaging changesHOUSTON, TX, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the "Company" or "Nexalin"), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain,...
FDA feedback provides clear framework for Nexalin's planned U.S. Pilot Study and supports a potential De Novo pathway for the Gen-2 SYNC™ device in Alzheimer's diseaseHOUSTON, TX, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the "Company" or "Nexalin"), the...
HOUSTON, TX, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (Nasdaq: NXL) is pleased to invite investors to a webinar on December 4, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will...
Peer-reviewed case report published in The American Journal on Addictions highlights significant clinical improvement and sustained abstinence following Nexalin's non-invasive therapyHOUSTON, TX, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency...